T. Rowe Price Investment Management
AMLX icon

T. Rowe Price Investment Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

T. Rowe Price Investment Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,517
Closed -$55K – 658
2025
Q4 		$55K Sell
4,517
-1,193,547
-100% -$16.2M ﹤0.01% 665
2025
Q3 		$16.3M Buy
+1,198,064
New +$11.3M 0.01% 523

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

T. Rowe Price Investment Management's AMLX Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 4,517 shares — an estimated $55K sold.

T. Rowe Price Investment Management first reported a position in AMLX in Q3 2025 and held it in 2 quarters. The position peaked at $16.3M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 4,517 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $55K.
  • T. Rowe Price Investment Management first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Amylyx Pharmaceuticals position peaked at $16.3M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.